FluoretiQ

Fluoretiq Ltd. was founded in 2017 in order to revolutionise the way antibiotic treatments are prescribed at POC (point-of-care) for diseases such as urinary tract infections and sexually transmitted diseases. NANOPLEX, its technology platform for future products, can identify and enumerate the presence and species of bacteria at the POC, 200 times faster than sending samples to a lab and waiting days for results to return. Products built on the Nanoplex platform will enable doctors to confirm infection within minutes, stopping the use of incorrect and unnecessary prescription of antibiotics, in-line with the global goal for antibiotic stewardship.